Biologics as a novel treatment option for palmoplantar pustulosis: a comprehensive review.

IF 1.4 4区医学 Q3 ALLERGY

Postepy Dermatologii I Alergologii Pub Date : 2024-06-01 Epub Date: 2024-06-30 DOI:10.5114/ada.2024.141128

Hio Fong Leong, Wen-Hui Wang, Fen Peng

{"title":"Biologics as a novel treatment option for palmoplantar pustulosis: a comprehensive review.","authors":"Hio Fong Leong, Wen-Hui Wang, Fen Peng","doi":"10.5114/ada.2024.141128","DOIUrl":null,"url":null,"abstract":"Introduction: Palmoplantar pustulosis (PPP) is a complex inflammatory skin disease. Currently, no standardized treatments exist, and traditional systemic therapies often display limited effectiveness and substantial adverse effects. Biologics, however, have shown potential for enhanced clinical outcomes in psoriasis patients, thereby prompting this investigation into their applicability in PPP treatment.Aim: This study constitutes the first comprehensive review to assess the effectiveness and underlying mechanisms of biologics for PPP.Material and methods: We conducted a PubMed search to identify studies on biologics for PPP from 1992 onward. The review focused on assessing the efficacy of biologics targeting cytokines like IL-1, IL-8, IL-17, IL-12/23, IL-36, and TNF-α.Results: Biologics for PPP are generally less effective than for psoriasis. Secukinumab and guselkumab, IL-17 and IL-23 inhibitors respectively, have shown better results compared to other biologics in trials. However, the effectiveness of other biologics remains uncertain due to limited data.Conclusions: More research is needed to find effective treatments for PPP, and selecting the right biologic for each patient is challenging.","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11253319/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Postepy Dermatologii I Alergologii","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5114/ada.2024.141128","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Palmoplantar pustulosis (PPP) is a complex inflammatory skin disease. Currently, no standardized treatments exist, and traditional systemic therapies often display limited effectiveness and substantial adverse effects. Biologics, however, have shown potential for enhanced clinical outcomes in psoriasis patients, thereby prompting this investigation into their applicability in PPP treatment.

Aim: This study constitutes the first comprehensive review to assess the effectiveness and underlying mechanisms of biologics for PPP.

Material and methods: We conducted a PubMed search to identify studies on biologics for PPP from 1992 onward. The review focused on assessing the efficacy of biologics targeting cytokines like IL-1, IL-8, IL-17, IL-12/23, IL-36, and TNF-α.

Results: Biologics for PPP are generally less effective than for psoriasis. Secukinumab and guselkumab, IL-17 and IL-23 inhibitors respectively, have shown better results compared to other biologics in trials. However, the effectiveness of other biologics remains uncertain due to limited data.

Conclusions: More research is needed to find effective treatments for PPP, and selecting the right biologic for each patient is challenging.

查看原文本刊更多论文

生物制剂作为治疗掌跖脓疱病的一种新方法：全面综述。

简介：掌跖脓疱病（PPP）是一种复杂的炎症性皮肤病：掌跖脓疱病（PPP）是一种复杂的炎症性皮肤病。目前，还没有标准化的治疗方法，传统的系统性疗法往往效果有限，且存在严重的不良反应。然而，生物制剂已显示出提高银屑病患者临床疗效的潜力，因此促使我们对其在 PPP 治疗中的适用性进行调查。目的：本研究是首次对生物制剂治疗 PPP 的疗效和基本机制进行评估的全面综述：我们在 PubMed 上进行了搜索，以确定 1992 年以来有关生物制剂治疗 PPP 的研究。综述重点评估了针对 IL-1、IL-8、IL-17、IL-12/23、IL-36 和 TNF-α 等细胞因子的生物制剂的疗效：结果：治疗 PPP 的生物制剂通常不如治疗银屑病有效。Secukinumab和guselkumab分别是IL-17和IL-23抑制剂，在试验中显示出比其他生物制剂更好的效果。然而，由于数据有限，其他生物制剂的疗效仍不确定：结论：需要开展更多的研究，以找到治疗 PPP 的有效方法，而为每位患者选择合适的生物制剂则具有挑战性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊